TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00483366

Intervention type: DRUG
Group type: OTHER
Intervention: capecitabine
Description: Dose level Capecitabine~-1 400 mg/m2 bid~0 500 mg/m2 bid~1. 500 mg/m2 bid~2. 600 mg/m2 bid~3. 600 mg/m2 bid~4. 725 mg/m2 bid~5. 725 mg/m2 bid~6. 850 mg/m2 bid~7. 850 mg/m2 bid

Intervention type: DRUG
Group type: OTHER
Intervention: gemcitabine hydrochloride
Description: Dose level Gemcitabine~-1 400 mg/m2 0 450 mg/m2~1. 550 mg/m2~2. 550 mg/m2~3. 675 mg/m2~4. 675 mg/m2~5. 825 mg/m2~6. 825 mg/m2~7. 1000 mg/m2

Intervention type: DRUG
Group type: OTHER
Intervention: imatinib mesylate
Description: Dose level Imatinib~-1 400 mg/d 0 400 mg/d~1. 400 mg/d~2. 400 mg/d~3. 400 mg/d~4. 400 mg/d~5. 400 mg/d~6. 400 mg/d~7. 400 mg/d

Intervention type: GENETIC
Group type: OTHER
Intervention: mutation analysis
Description: C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.

Intervention type: GENETIC
Group type: OTHER
Intervention: nucleic acid sequencing
Description: C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.

Intervention type: GENETIC
Group type: OTHER
Intervention: polymerase chain reaction
Description: C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
Study: NCT01225939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8329
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8329
Description: Solution
Study: NCT04117451

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Propolis
Description: Investigating the impact of propolis mouthwash on oral and cardiovascular health

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propolis
Description: Investigating the impact of propolis mouthwash on oral and cardiovascular health
Study: NCT01272648

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: RePCa A
Description: Intervention patients receives two consultations with a specialist oncology nurse three and six month after ended radiotherapy. The focus are on what is important for the patients at the specific time. The patient can bring his spouse.~Furthermore the patients have two physiotherapy consultations with guidance in pelvic floor exercises and an individual home-program of pelvic and functional training exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RePCa A
Description: Intervention patients receives two consultations with a specialist oncology nurse three and six month after ended radiotherapy. The focus are on what is important for the patients at the specific time. The patient can bring his spouse.~Furthermore the patients have two physiotherapy consultations with guidance in pelvic floor exercises and an individual home-program of pelvic and functional training exercises
Study: NCT02749045

Intervention type: RADIATION
Group type: OTHER
Intervention: SPECT imaging
Description: myocardial perfusion imaging
Study: NCT00768664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: 45 mg by continuous oral dosing
Study: NCT04038957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: SEP-363856 50mg, 75mg flexable dosing, dosed once daily capsule
Study: NCT01698593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5% + Epinephrine (1:200,000)
Study: NCT01794754

Intervention type: OTHER
Group type: OTHER
Intervention: Care as usual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Description: Occupational therapy in the waiting period before surgery. Occupational therapy comprises orthoses for the CMC-joint, hand exercises, and use of alternative working methods and assistive devices. The participants are encouraged to perform hand exercises three times a week for the first 12 weeks, and to use orthosis as much as possible, both during daytime (day orthosis) and night time (night orthosis).
Study: NCT02749955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PS-PrEP Intervention Group
Description: This group will involve working with a PS-PrEP social worker to learn about PrEP. The PS-PrEP social worker will help subjects develop a care plan based on the subject's decision about whether or not to use PrEP. This may include referrals for PrEP, other services, and/or HIV testing. Personal contact will continue by way of phone calls, and messages in between visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PrEPLine Control Group
Description: This group follows routine department of public health care as a Linkage to Care Specialist from the PrEPLine provides subjects with PrEP education and the ability to schedule an initial PrEP appointment. In addition to this care, subjects will be referred for additional testing for STIs/HIV and subjects will be given information about programs available to prevent HIV infection, which include PrEP.
Study: NCT00610324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium permanganate
Description: Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
Study: NCT01730040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
Study: NCT01908634

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk-based Strawberry Beverage without meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water-Based Strawberry Beverage without meal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk-based strawberry Beverage with meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water-Based strawberry Beverage with meal
Study: NCT02128789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elder Tree website
Description: Elder Tree is a private, secure information, support and communication website developed for this study.
Study: NCT01072357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin® (bevacizumab)
Description: One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl & Refresh Liquigel
Description: One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks
Study: NCT01730040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin over-encapsulated tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin over-encapsulated tablets orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin over-encapsulated tablets orally.
Study: NCT02615912

Intervention type: OTHER
Group type: OTHER
Intervention: PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5%

Intervention type: OTHER
Group type: OTHER
Intervention: Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5%

Intervention type: OTHER
Group type: OTHER
Intervention: Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5%

Intervention type: OTHER
Group type: OTHER
Intervention: Silwet* DA-63 (Momentive) 1.5%

Intervention type: OTHER
Group type: OTHER
Intervention: Sodium lauryl sulfate (Sigma Aldrich) 1.0%

Intervention type: OTHER
Group type: OTHER
Intervention: Water (control)
Study: NCT04286165

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief Peer Supported webSTAIR
Description: The BPS webSTAIR program is an online platform where individuals are taught skills in emotion regulation. In this program they will learn how to recognize the emotions they are feeling by assessing their own body language, being attentive to their thought processes, and attempting to replace negative behaviors with positive. Throughout the platform they will engage in written exercises to help them solidify the lessons with their own life experiencing. They will also have the support of peers throughout the program to help them when they need clarification or having a difficult time applying the lesson(s).
Study: NCT02159963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised training
Description: 8 weeks high intensity interval training, 3 times a week, one is supervised, two are home based unsupervised.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unsupervised training
Description: 8 weeks home based high-intensity-interval cycle-training 3 times a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optional training
Description: 8 weeks of optional home based, unsupervised training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: 8 weeks of control period. Participants are doing daily living.
Study: NCT00587418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: Arginaid (Novartis) 1 package (9.2g) bid for 7 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder 9.2g bid for 7 days
Study: NCT04097626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition education
Description: The experimental group will receive nutrition education once during the study. It will occur at the beginning of the second week. This will consist of a 30-minute interactive lecture and a 15-minute question-and-answer session. The information covered will be basic nutrition principles for good health and to support regular exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no nutrition education
Description: This group will not receive nutrition education.
Study: NCT02272400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IGRT for prone partial breast irradiation (PBI)
Description: IGRT for prone partial breast irradiation (PBI): All patients will be treated prone with 6 Gy/fraction delivered in 5 fractions over a 1-week period for a total dose of 30 Gy. Simulation and treatment will be started within 50 days from surgery in order to maximize the chances of optimal lumpectomy cavity visualization on the planning and cone beam CT scans. All patients will be followed monthly for the first 90 days then q3 months for the first year, then yearly for the next 10 years.
Study: NCT04450797

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: US -G VPS placement, done by BK Medical 5000 US with burr hole probe (type 9063 N11C5S, 11-5 MHz).
Description: US -G VPS placement, done by BK Medical 5000 US with burr hole probe (type 9063 N11C5S, 11-5 MHz).~Head not fixed, placed on horseshoe head holder, no preoperative navigation planning, catheter will be cut in length after positioning under real-time US guidance.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic navigation for VPS placement (Brainlab Dual Curve System with cranial navigation software version 3.1).
Description: Stereotactic navigation for VPS placement (Brainlab Dual Curve System with cranial navigation software version 3.1).~Head fixed in head clamp, entry point, trajectory and catheter length planned based on preoperative computer tomography imaging, catheter placed using navigated stylet.
Study: NCT01730040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin over-encapsulated tablets orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin over-encapsulated tablets orally.
Study: NCT03037749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Description: Alcohol beverage measured to have participant achieve a BAC of 0.08%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Description: Alcohol beverage measured to have participant achieve a BAC of 0.08%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo beverage
Description: Placebo beverage measured to mimic the smell and taste of the alcohol beverage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo beverage
Description: Placebo beverage measured to mimic the smell and taste of the alcohol beverage.
Study: NCT03495414

Intervention type: OTHER
Intervention: Brain Imaging
Description: * Structural MRI (T1 weighted)~* Diffusion Tensor Imaging (DTI)~* resting state functional MRI (rs-fMRI)~* functional MRI (fMRI): Brain activity will be measured in response to sexual images (visually evoked sexual arousal; processing of sexual stimuli), and importantly during a phase when these stimuli are anticipated (neural correlates of wanting and desire; reward anticipation).

Intervention type: OTHER
Intervention: Brain Imaging
Description: * Structural MRI (T1 weighted)~* Diffusion Tensor Imaging (DTI)~* resting state functional MRI (rs-fMRI)~* functional MRI (fMRI): Brain activity will be measured in response to sexual images (visually evoked sexual arousal; processing of sexual stimuli), and importantly during a phase when these stimuli are anticipated (neural correlates of wanting and desire; reward anticipation).
Study: NCT01730040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin over-encapsulated tablets orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe over-encapsulated tablet orally.
Study: NCT03495414

Intervention type: OTHER
Intervention: Cognitive testing
Description: We will administer neuropsychological tests assessing objective measures for~* intelligence (Ravens Matrices)~* impulsivity and risk-taking behavior (Balloon Analogue Risk Task)~* inhibitory control (Stop Signal Task).

Intervention type: OTHER
Intervention: Cognitive testing
Description: We will administer neuropsychological tests assessing objective measures for~* intelligence (Ravens Matrices)~* impulsivity and risk-taking behavior (Balloon Analogue Risk Task)~* inhibitory control (Stop Signal Task).

Intervention type: OTHER
Intervention: Psychometric
Description: Administered questionnaires include anxiety and depression symptoms (MADRS, HADS, GAD), drug use (AUDIT, DUDIT), attention deficits (ASRS), impulsivity (BIS-11), reward seeking behavior (BIS/BAS), sexual orientation, (hyper)sexual behavior, desire and compulsivity aspects (HDSI, HBI, SCS, SDI, SIS/SES).

Intervention type: OTHER
Intervention: Psychometric
Description: Administered questionnaires include anxiety and depression symptoms (MADRS, HADS, GAD), drug use (AUDIT, DUDIT), attention deficits (ASRS), impulsivity (BIS-11), reward seeking behavior (BIS/BAS), sexual orientation, (hyper)sexual behavior, desire and compulsivity aspects (HDSI, HBI, SCS, SDI, SIS/SES).
Study: NCT01730040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe over-encapsulated tablet orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin over-encapsulated tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for alirocumab and ezetimibe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for alirocumab and ezetimibe.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for alirocumab and ezetimibe.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for alirocumab and ezetimibe.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for alirocumab and ezetimibe.
Study: NCT03495414

Intervention type: OTHER
Intervention: Blood test
Description: Blood samples will be taken for routine health assessment, measurement of sex hormonal levels, HPA-axis function test (dexamethasone suppression), and potential DNA extraction and (epi)genetic profiling.

Intervention type: OTHER
Intervention: Blood test
Description: Blood samples will be taken for routine health assessment, measurement of sex hormonal levels, HPA-axis function test (dexamethasone suppression), and potential DNA extraction and (epi)genetic profiling.
Study: NCT01043471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum
Description: Subjects were instructed to chew gum at least 6 times a day in an effort to reduce snacking.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Subjects were instructed to drink 8 oz of water at least 6 times a day in an effort to reduce snacking.
Study: NCT01730040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for alirocumab and ezetimibe.
Study: NCT03947957

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: collection of expectoration, stools and blood
Description: collection of expectoration, stools and blood
Study: NCT01628315

Intervention type: DEVICE
Intervention: MRI
Description: Annual MRIs as part of participation in the ASA study.
Study: NCT04325646

Intervention type: OTHER
Intervention: Human Biological samples
Description: Blood samples for serological tests

Intervention type: OTHER
Intervention: Human Biological samples
Description: Blood samples for serological tests

Intervention type: OTHER
Intervention: Human Biological samples
Description: Blood samples for serological tests

Intervention type: OTHER
Intervention: Human Biological samples
Description: Blood samples for serological tests

Intervention type: OTHER
Intervention: Human Biological samples
Description: Blood samples for serological tests

Intervention type: OTHER
Intervention: Human Biological samples
Description: Blood samples for serological tests
Study: NCT02583945

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: kidney treatment bundle (KDIGO)
Description: Application of the measures of the kidney treatment bundle.
Study: NCT00409604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporary RV VVI pacing
Description: temporary pacing at the onset of revascularisation
Study: NCT03417180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: a rate of infusion of reminfentanil will be increased by 50% every 5 minutes, until SPI value decreases back to baseline level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: a rate of infusion of reminfentanil will be increased by 50% every 5 minutes, until SPI value decreases back to baseline level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: a rate of infusion of reminfentanil will be increased by 50% every 5 minutes, until SPI value decreases back to baseline level

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: surgical pleth index
Description: every time SPI value increases by 15 a rate of infusion of reminfentanil will be increased by 50% every 5 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: surgical pleth index
Description: every time SPI value increases by 15 a rate of infusion of reminfentanil will be increased by 50% every 5 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: surgical pleth index
Description: every time SPI value increases by 15 a rate of infusion of reminfentanil will be increased by 50% every 5 minutes
Study: NCT03381599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim Injection
Description: Filgrastim of 10 ug/kg/day will be given for four serial days.
Study: NCT04111458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1701963
Description: Tablet
Study: NCT04296500

Intervention type: OTHER
Intervention: Decision tree modeling
Description: A decision tree analysis was employed to explore the process of decision-making on types of pattern based on the existence or nonexistence of a symptom. At the end of tree presented is the proportion of patients who are categorised into each pattern.~In this study, the classification was performed by applying the classification and regression tree (CART) algorithm using Scikit-learn package of Python, which performs a division using the Gini coefficient or the decrement of dispersion. The Gini coefficient is one of the tools for measuring entropy or diversity in each node and it measures the decrement by comparing the information entropy before and after separation. To avoid overfitting, the maximum number of leaf nodes was limited to four and the pruning method which complied with the principle of minimum description length was applied.
Study: NCT02028546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bathing and moisturizer application
Description: regimen 1: soaking an arm for 10 minutes, no moisturizer application regimen 2: soaking an arm for 10 minutes,immediate moisturizer application regimen 3: soaking an arm for 10 minutes, delayed moisturizer application for 30 min.~regimen 4: wait for 10 minutes,no soaking, moisturizer application (moisturizer alone) (All regimens were completed in all patients with 2 visits (7 days interval))

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bathing and moisturizer application
Description: regimen 1: soaking an arm for 10 minutes, no moisturizer application regimen 2: soaking an arm for 10 minutes,immediate moisturizer application regimen 3: soaking an arm for 10 minutes, delayed moisturizer application for 30 min.~regimen 4: wait for 10 minutes,no soaking, moisturizer application (moisturizer alone) (All regimens were completed in all patients with 2 visits (7 days interval))
Study: NCT02396823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training
Description: Standard threshold Positive Expiratory Pressure Device and threshold Inspiratory Muscle Trainer assembled together using a T-shaped connector with flanged mouthpiece will be used. The participants will be instructed to perform inspiratory and expiratory efforts against a resistive load. Training session lasts 45 minutes per day, 5 days per week, for 4 weeks.